- Home
- Clinical Trial Unit
- Clinical & Research Trials
- Cancer Registry
- Publication
- Useful Links
- Team
- Testimonials
- News & Events
Shifa Clinical Research Center
Vision
To be a regional leader in innovative and groundbreaking clinical research, to advance medical knowledge (“Illaman Nafian”), and to improve the well-being of the community at large by fostering collaboration among researchers, clinicians, and industry partners.
Mission
To provide an unparalleled platform in the region, uniquely positioned to lead impactful, and ethical clinical research that transforms clinical practice on a global scale.
Director’s Message
Welcome to the Clinical Research Centre, where innovation, ethics, and dedication drive our mission to advance healthcare. We are committed to conducting groundbreaking research that not only transforms lives but does so with the utmost integrity and respect for the individuals and communities we serve. Through collaborative efforts with researchers, healthcare professionals, and industry leaders, we strive to pioneer solutions to the world’s most pressing medical challenges. Embracing cutting-edge technologies like artificial intelligence, we aim to enhance precision, accelerate timelines, and uphold the highest ethical standards in clinical trials,ensuring that our work remains patient-centered and socially responsible.
Prof. Dr. Maimoona Siddiqui
Director Shifa Clinical Research Center,
Shifa Center of Professional Excellence & Medical Education,
Shifa international Hospitals Ltd.,
Professor of Neurology, Shifa College of Medicine,
Shifa Tameer-e-Millat University Islamabad.
Contact Information
Shifa Clinical Research Center
Block A-0 Shifa International Hospitals, Ltd.,
Pitras Bukhari Road H-8/4, Islamabad – Pakistan
Telephone:
+92 – 51–8463984, +92 – 51–8463985
+92 – 51–8463385, +92 – 51–8464857
Shifa Clinical Research Center
Main Office A-0
Inpatient Unit
Research Reception A-0
Research Phlebotomy A-0
Clinical Trial Unit (CTU) A-0
Clinical Trial Repository (CTR) I-9
CTU Clinic
CLINICAL TRIAL APPROVAL PROCESS
Shifa Hospital Research Trials
| TRIALS NAMES | SPONSORS | STATUS |
|
HALT-IT Hemorrhage alleviation with tranexamic acid-intestinal system, Tranexamic acid of the treatment of gastrointestinal bleeding: An International randomized, double-blind placebo-controlled trial. |
 |
Completed Published in Trials https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3561-7 |
|
CRASH-3 Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomized, placebo-controlled trial |
|
Completed Published in The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32233-0/fulltext |
|
HIP ATTACK 1 Accelerated surgery versus standard care in hip fracture an international, randomized, controlled trial |
 |
Completed Published in The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30058-1/fulltext |
|
SafeHer Study A phase-III Prospective, two-cohort non-randomized Multicenter, Multinational, open-label study to assess the safety of assisted- and self-administered subcutaneous Trastuzumab as therapy in patients with operable her2-positive early breast cancer |
 |
Completed |
|
PERUSE Study A phase III prospective, two-cohort non-randomized, Multicenter, Multinational, open-label single arm study of pertuzumab in combination of as THERAPY in patients with operable Her2-positive early breast cancer |
|
Completed |
|
POISE-3 Perioperative Ischemic Evaluation-3 |
|
Completed Published in PubMed, NEJM |
|
Can Sino Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above |
 |
Completed Published in The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02753-7/fulltext |
|
COP-AF Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery |
|
Completed Published in ACC. |
|
Livzon Global Phase 3 Randomized Trial to evaluate efficacy, safety, immunogenicity of Recombinant SARS COV-2 fusion protein vaccine against COVID 19 in healthy adults after vaccination of 2 doses of inactivated vaccines |
 |
Completed Published in PubMed |
|
ALVOEYE A Randomized, Double-masked, Parallel-group, Multicenter
|
 |
Completed https://clinicaltrials.gov/ct2/show/NCT05155293
|
|
SEQIRUS A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus’ Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine when Administrated in Healthy Subjects aged 6 Months through 47 Months
|
 |
Completed https://www.clinicaltrials.gov/ct2/show/NCT03165617 |
|
BCD-201 A Randomized, Double-Blind Clinical Study of the Efficacy and Safety of BCD-201(JSC BIOCAD) and Keytruda® in Patients with Unresectable or Metastatic Melanoma |
 |
Completed |
|
GATES-MRI-301 A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain ofBifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants |
 |
Early closure by sponsor |
|
HIP ATTACK-2 Accelerated surgery versus standard care in hip fracture an international, randomized, controlled trial |
|
Actively recruiting |
|
ASPIRE-AF Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery |
|
Actively recruiting https://clinicaltrials.gov/ct2/show/NCT03968393
|
|
DEPOSITION Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery |
|
Early closure by sponsor https://clinicaltrials.gov/ct2/show/NCT03376061
|
|
ACTIV 2D Oral COVID-19 treatment (Protease Inhibitor) for stable outpatients |
 |
Completed https://clinicaltrials.gov/study/NCT05305547 |
|
Perjeta /BCD-178 BCD-178 (Biosimilar of pertuzumab) for Breast CA |
|
Follow-up Phase https://clinicaltrials.gov/study/NCT05738993 |
|
AI SAROSH Chart review of Gestational Diabetes patients |
 |
Actively recruiting https://aisarosh.com/ |
|
LIMIT To assess the feasibility of a large trial to evaluate the safety and efficacy of a common, lower INR target range in patients with bileaflet aortic mechanical valves. |
|
In Pipeline https://clinicaltrials.gov/study/NCT03636295 |
|
THE SHIPPS STUDY
A multi-institutional, prospective, controlled, randomized, double-blinded interventional trial to examine the potential benefits and risks of adjunctive hydrocortisone in Paediatric Septic shock. |
 |
In Pipeline https://clinicaltrials.gov/study/NCT03401398 |
Collaborators
Cancer Registry
A Gateway to Progress in Cancer Research
The Shifa Cancer Registry (SCR) is a hospital-based cancer registry initiated in 2018 to systematically collect accurate and comprehensive data on patients diagnosed and/or treated for cancer at Shifa International Hospital (SIH). It serves as a centralized database for the collection, storage, analysis, and interpretation of cancer-related data, ensuring thorough documentation of all cancer cases at SIH.
More Than Just Statistics
A cancer registry is not just a collection of statistics—it is a dynamic resource that plays a pivotal role in advancing cancer care. By sharing comprehensive, anonymized cancer data, the registry empowers researchers, clinicians, and public health professionals to drive innovation, optimize treatments, and develop effective prevention strategies.
Manuals
Growth in Cancer Cases (2018–2022)
The Shifa Cancer Registry recorded a 63.8% increase in cancer cases from 2018 to 2022
Together, we turn data into discovery, insight into impact, and hope into reality
Useful Links
Guidelines for Synopsis and Dissertation Writing for CPSP
National Institute of Health http://www.clinicaltrials.gov
Good Clinical Practices https://gcp.nidatraining.org/
Introduction to the Principles and Practice of Clinical Research
At SCRC, our greatest asset is our team. We’d like to introduce the dedicated professionals who advance our mission each day.
Symposium on “Clinical Trials in the Era of AI” organized by SCRC in collaboration with SCOPE and NUST
SCRC team at Joint Commission International (JCI) reaccreditation survey
Participation of SCRC team in an expert consultation organized by the World Health Organization (WHO), NHSRC, and DRAP.
A special mention of the SCRC team in the newsletter and praise from Dr. David Conen, Principal Investigator, ASPIRE-AF from Canada
Meeting with PJ Devereaux, principal scientist at PHRI, Canada, at SIHL to discuss the HIP-ATTACK2 and ASPIRE-AF trials.
SCRC team at 17th ANRD with Dr. Fahad being the organizer and Dr. Qasim being the moderator
Mr. Abdul Manan Kiani won 3rd prize in the 17th ANRD poster competition.
Meeting with NUST & PHC Global to review AI SAROSH progress and explore future collaboration.
SCRC team at the Symposium on the Future of Clinical Trials in Pakistan at Rehman Medical Institute (RMI), Peshawar.
Poster presentation by Dr. Sabahat and Dr. Sofia at the 14th International Public Health Conference, HSA, Islamabad.
Certificate Distribution for the first Pharmacy Residents’ Research Course
Meeting with Dr. Timo Tolppa, a UK-based global health researcher and coordinator of PPIE
Meeting of the SCRC team for Process Improvements and Workflows Development
Shifa International Hospital successfully concludes the first-ever SARS-CoV-2 Vaccine Trial (Phase III), commonly known as Casino-Bio Trial in Pakistan to defeat Covid-19. It lasted more than 2 years and recruited more than 17 thousand volunteers for this trial from five major institutions in Pakistan. Globally more than 44 thousand volunteers were recruited. At Shifa, more than 5480 volunteers participated and contributed to a major portion of data for this trial.
Shifa Clinical Research Center launched first cancer registry report comprised of 3 years of cancer data (n = 8988) from 2018 to 2020, which includes basic demographics, TNM stage, grade, cancer family history, and treatment of patients